Re: Farmas USA
ACOR
Acorda writes off another R&D program as Ampyra flops in stroke study
https://endpts.com/acorda-writes-off-another-rd-program-as-ampyra-flops-in-stroke-study/
ACOR
Acorda writes off another R&D program as Ampyra flops in stroke study
https://endpts.com/acorda-writes-off-another-rd-program-as-ampyra-flops-in-stroke-study/
HALO
announced that AbbVie (NYSE: ABBV) has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of a phase 1 study in which the target results were not achieved.
Cortos:
Mirate estas dos,
IMUC ,1er dia despues de R/s. Aunque me dice la TWS que no acciones disponibles y el operador que para localizarlas tengo que ponder OV a mercado.
MSTX- anuncia Merger o BO, y en pre market + 22.45 , en cuanto haga la 1ra resistencia intradia tendrá que caer acorde con la reglas de R.Fibo.
,
MSTX
Justo la estaba mirando. PEro de BO nada:
• Preliminary Indications of Interest in Reverse Merger Transactions. The Company has received several written indications of interest from privately-held companies, including companies with synergistic clinical-stage drug candidates, and is actively evaluating these opportunities.
• Other Strategic Opportunities. Concurrently, the Company will continue to explore ways to strategically monetize its vepoloxamer assets, including through licensing transactions.
• Continued Clinical Development of AIR001. In parallel with exploring strategic opportunities, the Company will continue to support ongoing and planned investigator-sponsored clinical studies of its lead asset, AIR001, for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).
"Our recently-announced strategic process has generated a number of opportunities that would be transformative for Mast," stated Brian M. Culley, Chief Executive Officer of Mast Therapeutics. "We are diligently and expeditiously reviewing these strategic alternatives, which we believe could maximize returns for our stockholders. We also remain excited about the potential for AIR001 in HFpEF and look forward to more data from investigator-sponsored studies in 2017," continued Mr. Culley.
MSTX,,
igual el tortazo es mañana y hoy no se cansa de subir, pero creo que la noticia no es para tanto , lo que si por especulación, debe iniciar una t.alcista con su lógica corrección, ojala acertemos y podamos entrar cuando sube y ponerse corto cuando baje, je,je
IMUC, esta a todas creo le toca bajar , es lo tipico tras un R/s
MSTX
Sí, la noticia es humo. Debería caer desde inicio. Me he metido con 17000 a 0,089. No me daban más :(
Fuera de DVAX, para un día bastate.
Ofd topicc
Magura, vigila el Banco Popular, que le ha llenado de cortos y no pinta bien, creo que la tienes a 1€, la tendencia es muy bajista, cuidado.
Que rabia cuando las sigues, sin estar dentro y se ponen en este plan. ALBO precio de cierre al 09 de noviembre cuando puse el comentario en los 17$, hoy en los 30$, en 8 sesiones......